Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 3/20 | 0.54 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 10/20 | 0.39 |
| ▸ | FLT1 | P17948 | 8/20 | 0.39 |
| ▸ | FLT4 | P35916 | 8/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17452594 | 0.87 | ROCK1 (0.52) | ROCK1TNKSPARP1PARP2KDR | |
| SCHEMBL1789261 | 0.75 | ATM (0.50) | ROCK1PARP1PARP2ATMNPSR1 | |
| SCHEMBL19902376 | 0.74 | ROCK1 (0.53) | ROCK1PARP1ATMNPSR1ROCK2 | |
| SCHEMBL19902393 | 0.73 | ROCK2 (0.41) | ROCK1PARP1PARP2ATMNPSR1 | |
| SCHEMBL19902535 | 0.71 | KDM4E (0.40) | ROCK1PARP1KDRROCK2NPC1 | |
| SCHEMBL15879378 | 0.70 | ROCK1 (1.00) | ROCK1KDRFLT1FLT4ATM | |
| SCHEMBL19902452 | 0.70 | SMN1; SMN2 (0.45) | ROCK1PARP1ATMNPSR1ROCK2 | |
| SCHEMBL1786994 | 0.70 | PRMT5 (0.48) | ROCK1PARP1PARP2ATMNPSR1 | |
| SCHEMBL1786583 | 0.70 | ATM (0.47) | ROCK1PARP1PARP2ATMNPSR1 | |
| SCHEMBL19902689 | 0.69 | ROCK2 (0.46) | ROCK1ROCK2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | ROCK1 1/4885TNKS 589/4885PARP1 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.